Open Targets

Open Targets is an innovative, public-private partnership between Bristol Myers Squibb, EMBL-EBI, GSK, Sanofi and Wellcome Sanger Institute, that uses human genetics and genomics data for systematic drug target identification and prioritisation.

UK DRI researchers can access resources offered by Open Targets through their target validation platform, which integrates public domain data to enable target identification and prioritisation, or the Open Targets Genetics Portal which identifies targets based on GWAS and functional genomics. Open Targets are already working with several UK DRI researchers and are open to develop additional collaborations on experimental projects to generate large datasets with UK DRI researchers, or to strengthen the target validation project.